Blood transfusion as a risk factor for non-Hodgkin lymphoma

被引:42
作者
Brandt, L [1 ]
Brandt, J [1 ]
Olsson, H [1 ]
Anderson, H [1 ]
Moller, T [1 ]
机构
[1] UNIV LUND HOSP,SO SWEDISH REG TUMOR REGISTRY,S-22185 LUND,SWEDEN
关键词
transfusion; risk factor; non-Hodgkin lymphoma;
D O I
10.1038/bjc.1996.220
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a case-control study of 280 out of 426 consecutive patients with a recent diagnosis of non Hodgkin lymphoma (NHL) and 1827 control subjects, 53 (19%) and 230 (13%) respectively had received blood transfusions 1 year or more before the interview. Using an age- and sex-stratified analysis the odds ratio (OR) for transfusion was 1.74 (95% CI 1.24-2.44). ORs were also determined for transfusions received in the intervals 1-5, 6-15, 16-25 and greater than or equal to 26 years before diagnosis. In the interval 6-15 years, the OR for transfusion was 2.83 (95% CI 1.60-4.99) whereas ORs for transfusions received in other intervals were lower and not significantly elevated. Histological diagnoses (Kiel classification) and results of staging procedures were known for 185 patients. For low-grade NHL of nodal B-cell chronic lymphocytic leukaemia (B-CLL) or immunocytoma type, the OR for transfusions was 4.15 (95% CI 1.92-9.01). For low-grade nodal lymphomas of follicle centre cell type and high-grade nodal lymphomas, no relation to transfusions could be demonstrated. For high-grade extranodal lymphoma as sole manifestation, OR for transfusions was 3.27 (95% CI 1.30-8.24). It is concluded that blood transfusion may be a risk factor for NHLs especially those of B-CLL or immunocytoma type and for high-grade extranodal lymphoma.
引用
收藏
页码:1148 / 1151
页数:4
相关论文
共 17 条
[11]   BENEFICIAL EFFECT OF AUTOLOGOUS BLOOD-TRANSFUSION ON INFECTIOUS COMPLICATIONS AFTER COLORECTAL-CANCER SURGERY [J].
HEISS, MM ;
MEMPEL, W ;
JAUCH, KW ;
DELANOFF, C ;
MAYER, G ;
MEMPEL, M ;
EISSNER, HJ ;
SCHILDBERG, FW .
LANCET, 1993, 342 (8883) :1328-1333
[12]   A SEARCH FOR UNKNOWN BLOOD-BORNE ONCOGENIC VIRUSES [J].
MEMON, A ;
DOLL, R .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (03) :366-368
[13]  
*NAT BOARD HLTH WE, 1995, CANC INC SWED 1992
[14]   INCIDENCE OF NON-HODGKIN-LYMPHOMA IN KIDNEY AND HEART-TRANSPLANT RECIPIENTS [J].
OPELZ, G ;
HENDERSON, R .
LANCET, 1993, 342 (8886-7) :1514-1516
[15]  
STANSFELD AG, 1988, LANCET, V1, P292
[16]  
STARZL TE, 1984, LANCET, V1, P583
[17]  
*STATACORP, 1995, STAT STAT SOFTW REL